Nasdaq

Mainz Biomed Enters Agreement with Quest Diagnostics to Advance ColoAlert Colorectal Cancer ...

Mainz Biomed N.V. has announced a partnership with Quest Diagnostics to commercialize its stool-based colorectal cancer screening test, ColoAlert, which detects tumor DNA to identify early-stage ...
Yahoo Finance

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory ...

BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ...
Yahoo Finance

Mainz Biomed partners with Quest for colorectal cancer screening test

Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal cancer screening test, ColoAlert. The test leverages polymerase chain ...
Investing

Guardant Health and Quest partner to expand blood-based cancer test

PALO ALTO/SECAUCUS - Guardant Health, Inc. (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX), a prominent player in the Healthcare Providers & Services industry with a market capitalization of $20.9 ...

Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth

Guardant Health grows with Shield blood CRC screening, Quest deal, 50M reach, 335% surge, and FY25 revenue $981M up 33%. Read ...